RK-582

RK-582 is a small molecule, orally active spiroindolinone-based inhibitor of tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), members of the poly(ADP-ribose) polymerase (PARP) family. It was discovered through lead optimization from earlier tankyrase inhibitors and exhibits robust tumor growth inhibition in preclinical models of colorectal cancer. Mechanistically, RK-582 selectively inhibits TNKS1/2 enzymatic activity, leading to stabilization and accumulation of AXIN proteins, which are negative regulators of Wnt/β-catenin signaling. This results in decreased β-catenin levels and downregulation of its target genes—key drivers in colorectal carcinogenesis. Preclinical studies have shown that RK-582 suppresses the growth of Wnt/β-catenin-dependent human colorectal cancer cells both in vitro and in xenograft mouse models. The drug is currently being evaluated for safety and tolerability in a first-in-human Phase 1 clinical trial for patients with unresectable metastatic or recurrent colorectal cancer[1][3][5][8].